Viracta Therapeutics (VIRX) Debt by Year
Viracta Therapeutics Inc carried $0 in long-term debt against $12.3M in cash and equivalents at the end of fiscal year 2023. Long-term debt fell 100.0% from the prior fiscal year. The table below carries 15 fiscal years, from 2009 to 2023, and the quarters Viracta Therapeutics Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
VIRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing | FY17Filing | FY16Filing | FY15Filing | FY14Filing | FY13Filing | FY12Filing | FY11Filing | FY10Filing | FY09Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $24.9M+416.2% | $4.8M+16.0% | $4.2M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $12.3M-66.5% | $36.8M-64.5% | $103.6M+119.9% | $47.1M+158.5% | $18.2M+33.0% | $13.7M-49.2% | $27.0M+234.9% | $8.1M-70.0% | $26.9M+21.2% | $22.2M+46.7% | $15.1M+1.2% | $14.9M+60.5% | $9.3M-34.5% | $14.2M+234.0% | $4.3M |
VIRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'24Filing | Q2'24Filing | Q1'24Filing | Q4'23Filing | Q3'23Filing | Q2'23Filing | Q1'23Filing | Q4'22Filing | Q3'22Filing | Q2'22Filing | Q1'22Filing | Q4'21Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $16.9Mn/m | $18.7M-9.8% | $18.7M-18.2% | $0-100.0% | $0-100.0% | $20.8M+327.8% | $22.8M+371.7% | $24.9M+416.2% | $4.9M-3.1% | $4.9M+17.0% | $4.8M+4.5% | $4.8M+16.0% |
| Cash & Equivalents | $13.1M+2.1% | $14.0M-2.2% | $12.1M-33.4% | $12.3M-66.5% | $12.9M-45.2% | $14.3M-82.5% | $18.1M-80.4% | $36.8M-64.5% | $23.5M-78.9% | $81.6M-33.5% | $92.2M-28.6% | $103.6M+119.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Viracta Therapeutics Inc financials
Frequently Asked Questions
Viracta Therapeutics Inc carried $0 in long-term debt against $12.3M in cash and equivalents at the end of fiscal year 2023.
Viracta Therapeutics Inc (VIRX) long-term debt fell by 100.0% year over year, from $24.9M to $0 in fiscal year 2023.
Viracta Therapeutics Inc (VIRX) reported $16.9M in long-term debt in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Viracta Therapeutics Inc (VIRX) reported on that line in every period on record.